Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?

Bibliography

• Lipton RB, Stewart WF, Diamond S, Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-57
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160
   PubMed Web of Science ®Google Scholar
• Stephen D. Silberstein. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
   PubMed Web of Science ®Google Scholar
• Diamond S, Wenzel R. Practical approaches to migraine management. CNS Drugs 2002;16(6):385-403
   PubMed Web of Science ®Google Scholar
• Sheftell FD, Feleppa M, Tepper SJ, Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 2004;44:661-8
   PubMed Web of Science ®Google Scholar
• Johnson MP, Fernandez F, Colson NJ, Griffiths LR. A pharmacogenomic evaluation of migraine therapy. Expert Opin Pharmacother 2007;8(12):1821-35
   PubMed Web of Science ®Google Scholar
• Lipton RB, Silberstein SD, Saper JR, Why headache treatment fails. Neurology 2003;60(7):1064-70
   PubMed Web of Science ®Google Scholar
• Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs 2010. [Epub ahead of print]
   Google Scholar
• Bigal ME, Krymchantowski AV. Emerging drugs for migraine prophylaxis and treatment. MedGenMed 2006;8(2):31
   PubMedGoogle Scholar
• Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 2008;28(8):877-86
   PubMed Web of Science ®Google Scholar
• Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006;46(Suppl 4):S171-81
   PubMed Web of Science ®Google Scholar
• Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003;43(2):144-66
   PubMed Web of Science ®Google Scholar
• Masterson CG, Durham PL. DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons. Headache 2010. [Epub ahead of print]
   Google Scholar
• Young WB. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives. Headache 1997;37(Suppl 1):S42-5
   Google Scholar
• Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1995;45(3 Pt 1):585-7
   PubMed Web of Science ®Google Scholar
• Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986;36(7):995-7
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990;30(6):334-9
   PubMed Web of Science ®Google Scholar
• Kabbouche MA, Powers SW, Segers A, Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache 2009;49(1):106-9
   PubMed Web of Science ®Google Scholar
• Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache 1994;34(10):578-80
   PubMed Web of Science ®Google Scholar
• Winner P, Dalessio D, Mathew N, Office-based treatment of acute migraine with dihydroergotamine mesylate. Headache 1993;33(9):471-5
   PubMed Web of Science ®Google Scholar
• Schran HF, Tse FLS, Chang C-T. Bioequivalence and safety of subcutaneously and intramuscularly administered dihydroergotamine in healthy volunteers. Curr Ther Res 1994;55:1501-8
   Web of Science ®Google Scholar
• Becker WJ, Riess CM, Hoag J. Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache 1996;36(3):144-8
   PubMed Web of Science ®Google Scholar
• Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol 1996;53(12):1285-91
   PubMedGoogle Scholar
• Ziegler D, Ford R, Kriegler J, Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994;44(3 Pt 1):447-53
   PubMed Web of Science ®Google Scholar
• Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators. Headache 1995;35(4):177-84
   PubMed Web of Science ®Google Scholar
• Berde B, Sturmer E. Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In: Berde B, Schild HO, editors. Ergot alkaloids and related compounds. Springer-Verlag, Berlin; 1978. p. 1-28
   Google Scholar
• Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology 1995;45(3 Pt 1):577-84
   PubMed Web of Science ®Google Scholar
• Griffith RW, Grauwiler J, Hodel C, Toxicological considerations. In: Berde B, Schild HO, editors. Ergot alkaloids and related compounds. Springer-Verlag, Berlin; 1978. p. 805-51
   Google Scholar
• Drugs@FDA: Dihydroergotamine mesylate. U.S. Food and Drug Administration. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=DIHYDROERGOTAMINE%20MESYLATE [Last accessed 16 June 2010]
   Google Scholar
• Drugs.com: MAP Pharmaceuticals Announces FDA Will Not Require a Second Pivotal Efficacy Study for Levadex NDA Submission. Available from: www.drugs.com/nda/levadex_100111.html#ixzz0pZ8bDuJt [Last accessed 16 June 2010]
   Google Scholar
• Cook RO, Shrewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache 2009;49(10):1423-34
   PubMed Web of Science ®Google Scholar
• Shrewsbury SB, Kori SH, Miller SD, Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Curr Med Res Opin 2008;24(7):1977-85
   PubMed Web of Science ®Google Scholar
• Shrewsbury SB, Cook RO, Taylor G, Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo) inhaler. Headache 2008;48(3):355-67
   PubMed Web of Science ®Google Scholar
• Sandoz Pharmaceuticals Corp., East Hanover, NJ. Data on file
   Google Scholar
• Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache 1997;37(Suppl 1):S33-41
   Google Scholar
• Schurks M, Rist PM, Bigal ME, Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Lipton RB. Dihydroergotamine. In: Olesen j, Tfelt-Hansen P, Welch KMA, editors. The headaches. Raven Press, New York; 1993. p. 313-22
   Google Scholar
• Mondell B, Giuliano R. A prospective evaluation of intramuscular dihydroergotamine for the control of acute migraine in the office setting: preliminary findings [Abstract]. Headache 1992;32:251-2
   Google Scholar
• Winner P, Dalessio D, Mathew N, Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine. Am J Emerg Med 1994;12(2):138-41
   PubMed Web of Science ®Google Scholar
• Schurks M. Dihydroergotamine: role in the treatment of migraine. Expert Opin Drug Metab Toxicol 2009;5(9):1141-8
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Howse D. In-patient treatment of chronic daily headache using dihydroergotamine: a long-term follow-up study. Can J Neurol Sci 1998;25(2):146-50
   PubMed Web of Science ®Google Scholar